Navigation Links
Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
Date:12/10/2008

k status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's perio
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
2. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
3. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
4. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
5. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
6. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
7. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
8. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
9. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... Industrial Applications , the global market for industrial enzymes ... 2018, registering a five-year compound annual growth rate (CAGR) ... in the detergent enzyme segment with a CAGR of ... influenced almost every sector of industrial activity, ranging from ...
(Date:7/30/2014)... 2014  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... List of Outstanding Issues (LOI) from the European Medicines ... for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone ... drug candidate being evaluated for weight loss. ... point were adequately addressed by the Company based in ...
(Date:7/30/2014)... July 30, 2014   Epic Sciences, Inc. ... novel diagnostics to personalize and advance the treatment and ... Gregory T. Lucier as chairman of Epic,s board ... of Life Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s ... its circulating rare cell analysis platform with special focus ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 NCERC ... Athmanathan will present his findings on corn stover ... conference this week in Washington, D.C. , ... Energy conference is a testament to the success ... Caupert said. “Thanks to the foresight and vision ...
Breaking Biology Technology:Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... AMSTERDAM, November 30 Biopharmaceutical company Kiadis,Pharma ... in its,multinational registration clinical trial with ATIR(TM). The study ... after one,year following an allogeneic stem cell transplantation with ... an allogeneic,stem cell transplantation but without having a matched ...
... , ... Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; ,China Yongxin,Pharmaceuticals, ... pharmaceuticals in Northeastern China, today announced it has,completed preparation ... , The Chinese government recently ...
... NOVATO, Calif., Nov. 30 BioMarin Pharmaceutical Inc. (Nasdaq: ... Drug Administration (FDA) has granted orphan drug designation for ... Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has previously ... in October 2009, the Committee for Medicinal Products for ...
Cached Biology Technology:Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4
(Date:7/30/2014)... humans figured out how to create colors, nature had ... wings of many different hues, for example. Now scientists ... environmentally friendly way to make colored plastics. Their paper ... of materials rather than dyes, to produce color ... , N. Asger Mortensen, Anders Kristensen and colleagues point ...
(Date:7/30/2014)... professor from Wayne State University,s College of Engineering ... Science Foundation for the project, "Nanoparticle-directed synthesis of ... Science Foundation, nanotechnology is the creation and utilization ... properties and functions. A major bottleneck in scaling ... that connect different functional materials into one device. ...
(Date:7/30/2014)... therapies for spinal cord injury (SCI), traumatic brain injury ... great deal has been learned over the past 30 ... factors that regulate axon growth, but this large body ... therapeutics. Prof. Lemmon and his team from University of ... root causes, but a consensus is emerging that one ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... Eucalyptus trees - or gum trees as they are know - ... system and depositing it their leaves and branches., Scientists from CSIRO ... Nature Communications . "The eucalypt acts as a hydraulic ... and draw up water containing the gold. As the gold is ...
... prominence as research reagents in modern biological science labs, ... lot can differ significantly from the next, in terms ... loss of countless hours of research, to say nothing ... antigen is a substance that stimulates the production of ...
... Clemson University scientists are working to determine how ... for neurological disorders like Tuberous Sclerosis Complex (TSC). ... growth of tumors in the brain and other vital ... and cognitive impairment that may arise from the abnormal ...
Cached Biology News:There's gold in them thar trees 2The hitchhiker antigen: Cause for concern? 2Clemson University study points to possible treatment for brain disorders 2
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Parathyroid Hormone Receptor 2 [PTHR2]...
... a proprietary high-performance desalting resin, exclusive to ... characteristics compared to other commercially available resins. ... of protein can be processed, providing exceptional ... salts and other small molecules ( ...
... member of the caudal-related homeobox family, is ... proliferation and differentiation in intestinal epithelial cells. ... cells towards the phenotype of differentiated villus ... of the phenotype. Clone CDX2-88 reacts with ...
Biology Products: